European Commission Approves Merck and Pfizer/Astellas Combination Therapy for Bladder Cancer
The European Commission has granted approval for a combination treatment consisting of Merck's Keytruda (pembrolizumab) and the Padcev (enfortumab vedotin) regimen, developed by Pfizer and Astellas. This therapy is indicated as a perioperative treatment for patients with resectable muscle-invasive bladder cancer (MIBC). This approval marks a significant milestone in the European market, as it represents the first time a PD-1 inhibitor has been approved for this specific use in the region. The combination aims to improve outcomes for patients facing surgical intervention for advanced bladder cancer.
Topics: Biotechnology European Commission Healthcare Oncology